A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging

Cell

Volumn 174, Issue 6, 2018, Pages 1373-1387.e19

  Keren, Leeat ^a   Bosse, Marc ^a   Marquez, Diana ^a   Angoshtari, Roshan ^a   Jain, Samir ^a   Varma, Sushama ^a   Yang, Soo Ryum ^a   Kurian, Allison ^a   Van Valen, David ^b,c   West, Robert ^a   Bendall, Sean C ^a   Angelo, Michael ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^c California Institute of Technology   (United States)

Author keywords

Breast Cancer; Checkpoint; Imaging; Mass spectrometry; MIBI; Multiplexed Ion Beam Imaging; Proteomics; Systems Biology; Tumor Immunology; Tumor Microenvironment

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD223 ANTIGEN; CD274 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE SEGMENTATION; IMAGING; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MULTIPLEXED ION BEAM IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIME OF FLIGHT MASS SPECTROMETRY; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNE MICROENVIRONMENT; TUMOR MICROENVIRONMENT; CLUSTER ANALYSIS; CYTOLOGY; DIAGNOSTIC IMAGING; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE; MACHINE LEARNING; MASS SPECTROMETRY; METABOLISM; MORTALITY; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; SPATIAL ANALYSIS;

ANTIGENS, CD; B7-H1 ANTIGEN; CLUSTER ANALYSIS; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MACHINE LEARNING; MASS SPECTROMETRY; PRINCIPAL COMPONENT ANALYSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SPATIAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85052874515     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.08.039     Document Type: Article

References (53)

1. Andre, F., Dieci, M.V., Dubsky, P., Sotiriou, C., Curigliano, G., Denkert, C., Loi, S., Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin. Cancer Res. 19 (2013), 28–33.
2. Andrews, L.P., Marciscano, A.E., Drake, C.G., Vignali, D.A.A., LAG3 (CD223) as a cancer immunotherapy target. Immunol. Rev. 276 (2017), 80–96.
3. Angelo, M., Bendall, S.C., Finck, R., Hale, M.B., Hitzman, C., Borowsky, A.D., Levenson, R.M., Lowe, J.B., Liu, S.D., Zhao, S., et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20 (2014), 436–442.
4. Bagaitkar, J., Cellular dynamics of resolving inflammation. Blood 124 (2014), 1701–1703.
5. Bendall, S.C., Simonds, E.F., Qiu, P., Amir, A.D., Krutzik, P.O., Finck, R., Bruggner, R.V., Melamed, R., Trejo, A., Ornatsky, O.I., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332 (2011), 687–696.
6. Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A.W., Savage, M.I., Osborne, C.K., Hilsenbeck, S.G., Chang, J.C., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21 (2015), 1688–1698.
7. Burugu, S., Gao, D., Leung, S., Chia, S.K., Nielsen, T.O., LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann. Oncol. 28 (2017), 2977–2984.
8. Carrel, S., Schmidt-Kessen, A., Giuffrè, L., Recombinant interferon-γ can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur. J. Immunol. 15 (1985), 118–123.
9. Chen, D.S., Mellman, I., Elements of cancer immunity and the cancer-immune set point. Nature 541 (2017), 321–330.
10. Chen, K.H., Boettiger, A.N., Moffitt, J.R., Wang, S., Zhuang, X., RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science, 348, 2015 aaa6090.
11. Chevrier, S., Levine, J.H., Zanotelli, V.R.T., Silina, K., Schulz, D., Bacac, M., Ries, C.H., Ailles, L., Jewett, M.A.S., Moch, H., et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell 169 (2017), 736–749.
12. Coskun, A.F., Cai, L., Dense transcript profiling in single cells by image correlation decoding. Nat. Methods 13 (2016), 657–660.
13. Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B.M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28 (2010), 105–113.
14. Denkert, C., Liedtke, C., Tutt, A., von Minckwitz, G., Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 389 (2017), 2430–2442.
15. Di Minin, G., Bellazzo, A., Dal Ferro, M., Chiaruttini, G., Nuzzo, S., Bicciato, S., Piazza, S., Rami, D., Bulla, R., Sommaggio, R., et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol. Cell 56 (2014), 617–629.
16. Disis, M.L., Stanton, S.E., Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am. Soc. Clin. Oncol. Educ. Book 35 (2015), e25–e30.
17. Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N., Lascar, R.M., Brown, D., Gilson, R.J., Tedder, R.J., et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137 (2009), 1289–1300.
18. Fortis, S.P., Sofopoulos, M., Sotiriadou, N.N., Haritos, C., Vaxevanis, C.K., Anastasopoulou, E.A., Janssen, N., Arnogiannaki, N., Ardavanis, A., Pawelec, G., et al. Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. J. Immunother. Cancer, 5, 2017, 39.
19. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
20. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167 (2016), 397–404.
21. Giesen, C., Wang, H.A.O., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., Schüffler, P.J., Grolimund, D., Buhmann, J.M., Brandt, S., et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11 (2014), 417–422.
22. Haralick, R.M., Shanmugam, K., Dinstein, I., Textural Features for Image Classification. IEEE Trans. Syst. Man. Cybern. SMC 3 (1973), 610–621.
23. Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
24. Huang, W., Hennrick, K., Drew, S., A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum. Pathol. 44 (2013), 29–38.
25. Kouzarides, T., Chromatin modifications and their function. Cell 128 (2007), 693–705.
26. Kwa, M.J., Adams, S., Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer 124 (2018), 2086–2103.
27. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373 (2015), 23–34.
28. Lee, J.H., Daugharthy, E.R., Scheiman, J., Kalhor, R., Yang, J.L., Ferrante, T.C., Terry, R., Jeanty, S.S.F., Li, C., Amamoto, R., et al. Highly Multiplexed Subcellular RNA Sequencing in Situ. Science 343 (2014), 1360–1363.
29. Lehmann, B.D., Jovanović, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., Sanders, M.E., Pietenpol, J.A., Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 11, 2016, e0157368.
30. Maleki Vareki, S., Garrigós, C., Duran, I., Biomarkers of response to PD-1/PD-L1 inhibition. Crit. Rev. Oncol. Hematol. 116 (2017), 116–124.
31. Matos, L.L., Trufelli, D.C., de Matos, M.G.L., da Silva Pinhal, M.A., Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark. Insights 5 (2010), 9–20.
32. Meyer, F., Topographic distance and watershed lines. Signal Process. 38 (1994), 113–125.
33. Munn, D.H., Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr. Med. Chem. 18 (2011), 2240–2246.
34. Muro, K., Chung, H.C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J.P., Golan, T., Le, D.T., Burtness, B., et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17 (2016), 717–726.
35. Nirschl, C.J., Drake, C.G., Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin. Cancer Res. 19 (2013), 4917–4924.
36. Oelkrug, C., Ramage, J.M., Enhancement of T cell recruitment and infiltration into tumours. Clin. Exp. Immunol. 178 (2014), 1–8.
37. Ott, P.A., Hodi, F.S., Kaufman, H.L., Wigginton, J.M., Wolchok, J.D., Combination immunotherapy: a road map. J. Immunother. Cancer, 5, 2017, 16.
38. Patel, S.P., Kurzrock, R., PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol. Cancer Ther. 14 (2015), 847–856.
39. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (2015), 2006–2017.
40. Ribas, A., Wolchok, J.D., Cancer immunotherapy using checkpoint blockade. Science 359 (2018), 1350–1355.
41. Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., et al., International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26 (2015), 259–271.
42. Schneider, C.A., Rasband, W.S., Eliceiri, K.W., NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9 (2012), 671–675.
43. Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17 (2016), 956–965.
44. Teng, M.W.L., Ngiow, S.F., Ribas, A., Smyth, M.J., Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 75 (2015), 2139–2145.
45. Troncone, G., Gridelli, C., The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?. Transl. Lung Cancer Res. 6:Suppl 1 (2017), S74–S77.
46. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
47. Van Gassen, S., Callebaut, B., Van Helden, M.J., Lambrecht, B.N., Demeester, P., Dhaene, T., Saeys, Y., FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87 (2015), 636–645.
48. Van Valen, D.A., Kudo, T., Lane, K.M., Macklin, D.N., Quach, N.T., DeFelice, M.M., Maayan, I., Tanouchi, Y., Ashley, E.A., Covert, M.W., Deep Learning Automates the Quantitative Analysis of Individual Cells in Live-Cell Imaging Experiments. PLoS Comput. Biol., 12, 2016, e1005177.
49. Weis, S.M., Cheresh, D.A., Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17 (2011), 1359–1370.
50. Woo, S.-R., Turnis, M.E., Goldberg, M.V., Bankoti, J., Selby, M., Nirschl, C.J., Bettini, M.L., Gravano, D.M., Vogel, P., Liu, C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72 (2012), 917–927.
51. + regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res. Treat. 163 (2017), 21–35.
52. Yu, L.-Y., Tang, J., Zhang, C.-M., Zeng, W.-J., Yan, H., Li, M.-P., Chen, X.-P., New Immunotherapy Strategies in Breast Cancer. Int. J. Environ. Res. Public Health, 14, 2017, E68.
53. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375 (2016), 819–829.